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Chronic pulmonary infection with Pseudomonas aeruginosa is responsible for most of the morbidity and mortality in cystic fibrosis (CF).
Once established as a biofilm, chronic P. aeruginosa infection caused by the mucoid phenotype cannot be eradicated. However, a period of
intermittent colonization with P. aeruginosa precedes the establishment of the chronic infection. This window of opportunity can be utilized
to eradicate P. aeruginosa from the respiratory tract of CF patients by means of oral ciprofloxacin in combination with nebulized colistin for
3 weeks or, even better, for 3 months or by means of inhaled tobramycin as monotherapy for 4 weeks or longer. This early, aggressive
eradication therapy has now been used for 15 years without giving rise to resistance to the antibiotics and without serious side effects. The
therapeutic results have been very successful and have completely changed the epidemiology in the Danish Cystic Fibrosis Center and a few
other centers which have used this strategy for several years. The chronic P. aeruginosa lung infection is not seen in CF infants and children
anymore due to the aggressive therapy, and no other bacteria have replaced P. aeruginosa in these young patients. The aggressive therapy has
been shown to very cost-effective, and a European Consensus report recommends this approach.
D 2005 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.1. Introduction
Chronic Pseudomonas aeruginosa lung infection is the
most prevalent infection of cystic fibrosis (CF) patients
[1]. This infection is responsible for most of the morbidity
and mortality of CF patients [2,3]. Once acquired, chronic
P. aeruginosa infection cannot be eradicated, and the
current strategy is therefore to maintain the lung function
of the patients by giving chronic suppressive antibiotic
therapy (maintenance therapy) for decades [1,2]. This is,
however, a costly therapy [4] with many side-effects such
as allergy and resistance to the antibiotics [5,6]. For-
tunately, the old medical dogma Fprevention is better than
cure_ also applies for P. aeruginosa infection in CF
patients, since a combination of prevention of cross-
infection and early aggressive antibiotic therapy of
intermittent P. aeruginosa colonization can prevent
chronic P. aeruginosa infection in most CF patients
[2,7–9].1569-1993/$ - see front matter D 2005 Published by Elsevier B.V. on behalf of E
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Although some centers such as the Danish CF Center in
Copenhagen follow their patients by monthly control in the
out-patient clinic, most patients are only examined every 4
months unless otherwise indicated, e.g., by the clinical
condition [8]. That means that distinction between inter-
mittent colonization and chronic infection becomes difficult,
since a respiratory culture positive for P. aeruginosa may
reflect either continuous colonization for nearly 4 months or
acquisition of the bacteria the day before the examination.
An epidemiological study was carried out in the Danish CF
Center which showed that the continuous presence of P.
aeruginosa in the lower respiratory tract for 6 months
indicated that the bacteria would never disappear [10].
Subsequently, based on early work of Burns and May [11],
an antibody method was developed [12,13] which could
distinguish between intermittent colonization and chronic
infection with a predictive value of a positive and a negative
test of 93% and 89%, respectively [14]. The antibody
method for diagnosing chronic P. aeruginosa infection was
further developed in subsequent publications which showed
that a similar diagnostic performance could be obtained withs 4 (2005) 49 – 54uropean Cystic Fibrosis Society.
Fig. 1. Bacteriological results of treatment of cystic fibrosis patients with
intermittent P. aeruginosa colonization with either oral ciprofloxacin and
nebulized colistin or with no treatment for 3 weeks. Two years follow-up [37].
Table 2
Off-label use of colistin for inhalation and use of Tobi\ in the Danish CF
Center, Copenhagen
& R-60 high-flow\+Sidestream\, Ventstream\, Mediaid nebulisation
chamber\, 8 L/min
& 10-min inhalation of bronchodilatory drug
& PEP mask for 10 min
& Off-label use of colistin 1–2 mio. units dissolved in 2–4 mL isotonic
sterile saline is inhaled for 10–15 min t.i.d.
& Tobi\ 300 mg b.i.d. for 1 month, Pari LC Plus\ nebulizor for 15 min
& Cleaning of the inhalation equipment with 70% ethanol, or heating to
80 -C for 10 min, or boiling for 1 min
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ent P. aeruginosa antigens [15–26]. In most patients, an
average period of 12 months of intermittent colonization
precedes chronic infection, but the individual variation is
large, and approximately 10% of the patients will continue as
chronically infected directly after the first positive culture
and these patients harbour mucoid strains [27,28]. The
current definition of chronic P. aeruginosa infection (con-
tinuous presence of P. aeruginosa in the lower respiratory
secretions for 6 months and/or 2 precipitating antibodies
against P. aeruginosa) is therefore based on the published
results summarized above and has been in use in the Danish
CF Center for the last 30 years. Similar definitions have now
been adopted by others [1,8,29]. Intermittent P. aeruginosa
colonization is therefore the presence of P. aeruginosa in
lower respiratory tract secretions for <6 months continu-
ously and normal level of antibodies against P. aeruginosa
[2]. It should, however, be realized, that many patients will
experience repeated intermittent colonization of P. aerugi-
nosa throughout their entire life, e.g., the 1-year period
prevalence of intermittent P. aeruginosa colonization is 15–
20% in the Danish CF Center [30].3. Colistin and ciprofloxacin as eradication therapy
The principles of antibiotic therapy in the Danish CF
Center have always been to keep bacteria away from theTable 1
Improved prevention of chronic P. aeruginosa infection by early treatment
of intermittent colonization [38]
& Introduction of ‘‘early treatment’’ according to a fixed treatment protocol
– 1st isolate: 3 weeks inhaled colistin (1 mio. units b.i.d.) +oral
ciprofloxacin (10–20 mg/kg b.i.d.)
– 2nd isolate: 3 weeks inhaled colistin (2 mio. units t.i.d.) + oral
ciprofloxacin (10–20 mg/kg b.i.d.)
– 3rd and subsequent isolates: 3 months inhaled colistin (2 mio. units
t.i.d.)+oral ciprofloxacin (10–20 mg/kg b.i.d.)lower respiratory tract of CF patients using early aggressive
antibiotic therapy based upon the monthly examination of
lower respiratory tract secretions whether there are clinical
symptoms or not [31]. This bacteriological approach was
successfully used to treat, e.g., S. aureus, H. influenzae and
S. pneumoniae, but it could not be used for P. aeruginosa in
the out-patient clinic until ciprofloxacin was marketed 20
years ago as the first oral antibiotic active against P.
aeruginosa. However, ciprofloxacin was restricted to adult
patients at that time although subsequent investigations
showed that the use in children could be justified without
any risk [32]. Since penetration of antibiotics to CF
respiratory secretions was low [33], it was thought that a
combination of oral and nebulized antibiotics would be
preferable. Since Littlewood et al. [34] had shown that
colistin inhalation reduced the number of lower respiratory
samples containing P. aeruginosa in CF patients with early
colonization and since development of resistance to that
drug was rare [35] and colistin inhalation was already used
for maintenance therapy of chronic infection [36], it was
decided to combine nebulized colistin with oral ciproflox-
acin in a randomized, controlled study compared to no
treatment of CF patients with intermittent P. aeruginosa
colonization [37]. The outcome was very encouraging, since
it was possible to prevent chronic P. aeruginosa infection in
85% of the treated patients compared to only 42% in the
non-treated patients ( p <0.05) (Fig. 1) [37]. Furthermore, aFig. 2. Bacteriological results of treatment of intermittent P. aeruginosa
colonization in CF patients with either 3 weeks or 3 months of oral
ciprofloxacin and nebulized colistin. Forty-two patients were included in
the study.
Fig. 3. Age distribution of CF patients with chronic P. aeruginosa lung infection treated at the Danish CF Center in Copenhagen 2001. The youngest patient
with chronic P. aeruginosa infection was 14 years.
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controls showed that the results were consistent and
correlated to improved lung function in the treated patients
[38]. Since not all CF patients got rid of P. aeruginosa
colonization, an intensified treatment protocol was devel-
oped (Tables 1–2) [38] which subsequently was shown to
give a longer period free from P. aeruginosa until the next
positive culture occurred (Fig. 2).4. Changing epidemiology of chronic P. aeruginosa
infection
The early aggressive therapy against intermittent P.
aeruginosa colonization has been used since 1989 in the
Danish CF Center and the results have completely changed
the epidemiology of chronic P. aeruginosa lung infection in
the Danish CF patients [30]. No CF infant or child has
contracted chronic P. aeruginosa infection since 1990, andFig. 4. Specific anti-P. aeruginosa antibody levels (ELISA) in relation to
treatment of a CF patient with intermittent non-mucoid P. aeruginosa
colonization.this infection is now only a problem in CF patients >14
years old (Fig. 3), and P. aeruginosa has not been replaced
by chronic infections caused by other bacteria in CF
children. The long-term results have now been confirmed
by others [39,40].5. Management of individual CF patients
Since CF patients may experience repeated intermittent P.
aeruginosa colonization, they will be subject to repeated
courses of anti-pseudomonal therapy, and measurements of
the antibody response in such cases can be helpful in the
management of the infection as illustrated in Figs. 4–5. Fig. 4
shows a patient who presented five Pseudomonas-positive
cultures during 88 months and who was treated successfully
with 3 weeks and 3 months courses of ciprofloxacin
combined with colistin. The antibody response to P.Fig. 5. Specific anti-P. aeruginosa antibody levels (ELISA) in relation to
treatment of a CF patient with early chronic mucoid P. aeruginosa
infection.
Table 3
Prevention of chronic P. aeruginosa infection by aggressive eradication of
intermittent colonization is cost-effective in CF patients [4]
& Average cost for a CF pediatric patient in Germany: 24,000 Euro per year
& The annual cost for a CF paediatric patient with chronic P. aeruginosa
infection is more than 3 times higher (36,400 Euro) than the cost for a CF
paediatric patient without infection (10,900 Euro) and 2 times higher
than intermittently colonized patients (17,500 Euro), based on the results
in the CF Center in Hannover, Germany (n =138, 49% with chronic
P. aeruginosa infection)
& Delaying onset of chronic P. aeruginosa infection with 1 year would save
>25,000
– 18,000 Euro per patient per year
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became significantly elevated and, eventually, the antibodies
decreased. The second patient (Fig. 5) was more difficult
since he initially was colonized with a mucoid P. aeruginosa
strain and produced seven positive cultures within 18months.
He was therefore treated intravenously with tobramycin and
anti-pseudomonal h-lactam antibiotics in addition to cipro-
floxacin orally and colistin inhalation. In spite of the therapy,
his antibody response became significantly elevated indicat-
ing chronic infection. After additional therapy including
tobramycin inhalation (Table 2), he eventually got rid of P.
aeruginosa and the antibody response decreased.6. Lack of side-effects
In spite of the use of colistin and ciprofloxacin for early
aggressive therapy against intermittent P. aeruginosa
colonization for 15 years, there have been no antibiotic
resistance problems in contrast to the situation in chronically
infected CF patients [6,42]. The reason is most likely that
the number of P. aeruginosa bacteria is lower during
intermittent colonization and the probability of mutations
therefore also lower. The patients have tolerated the therapy
without major side-effects [36,37].7. Use of other antibiotics for early eradication therapy
In addition to ciprofloxacin and colistin treatment of
intermittent P. aeruginosa colonization, other antibiotics
and protocols have also been used and proven to be
effective, e.g., inhalation of tobramycin 80 mg b.i.d. for 1
year or 300 mg b.i.d for 28 days [8,43–49]. Subsequent
typing of re-occurring P. aeruginosa strains showed that, in
approximately 75%, it was a new strain [45].8. Summary—the window of opportunity
The reason why the early aggressive eradication therapy
of intermittent P. aeruginosa infection has been so
successful is probably that it focuses on the only windowof opportunity which exists before the chronic, mucoid
biofilm-growing P. aeruginosa prevents successful eradica-
tion therapy of the lung infection in CF patients [48].
Furthermore, the successful therapy has drawn the attention
of clinicians on the idea that CF bronchopulmonary disease
is initiated by infection in the lower airways and is
accompanied by airways obstruction as a later and
presumably secondary feature [50,51]. It is therefore
important that clinicians should focus more on early
childhood prevention and treatment of lower respiratory
tract infection and inflammation in CF, and in this respect,
eradication of P. aeruginosa colonization has been proven
to be very successful and cost-effective (Table 3) [4]. The
early aggressive eradication therapy is therefore expected to
contribute to the continuing improvement of the survival of
CF patients [8,50,52]. A European Consensus Report has
now recommended this approach [8].References
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